SciSparc Ltd. announced initial positive pre-clinical results for treatment for obesity and the potential treatment of metabolic syndromes using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY). The results are in connection with the provisional patent application for treating metabolic syndromes including obesity with Clearmind based on SciSparc's CannAmide™'s active ingredient Palmitoylethanolamide and Clearmind's MEAI, submitted in September 2022. Clearmind's study, was conducted at the Hebrew University of Jerusalem, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns.

It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization, and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed.

Additionally, the treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group. Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli.

Thus, this treatment may be beneficial for the treatment of compulsive-reward-seeking behavior or excessive consumption of sweet foods.